Cowslip (Primula veris L.): A Comprehensive Reference
1. Identity and Botanical Profile
1.1 Taxonomy and Nomenclature
Cowslip, known scientifically as Primula veris, is a perennial herbaceous plant within the Primulaceae family. A widely cited synonym is Primula officinalis (L.) Hill. The species epithet veris, meaning "of spring," is the genitive case of the Latin ver ("spring"). The genus name Primula means "little earliest one" and is the feminine diminutive of the Latin primus.
Historical common names include cuy lippe, herb peter, paigle or pagil, peggle, key flower, key of heaven, fairy cups, petty mulleins, crewel, buckles, palsywort, and plumrocks. The name "cowslop," derived from Old English, still exists in some dialects, but the politer-sounding cowslip became standard in the 16th century.
The cowslip may be confused with the closely related Primula elatior (oxlip), which has a similar general appearance and habitat, although the oxlip has larger, pale yellow flowers more like a primrose, and a corolla tube without folds. Both species are covered by European regulatory monographs for the same herbal preparations.
1.2 Botanical Description and Habitat
Primula veris is a variable evergreen or semi-evergreen perennial plant growing to 25 cm tall and broad, with a rosette of leaves 5–15 cm long and 2–6 cm broad. The deep yellow flowers are produced in spring, in clusters of 10–30 blooms together on a single stem, with each flower 9–15 mm broad.
Primula veris is native to Europe, where it grows abundantly in temperate regions, and to Asia. Its wild habitat includes free-drained, grasslands, herb-rich meadows in woodland or scrub rides and edges, and calcareous rocks. It has also been introduced and naturalized in eastern North America.
1.3 Plant Parts Used and Preparations
Both the dried rootstocks (rhizomes) with the attached long, dried roots (primrose root — Primulae radix) and the dried flowers (Primulae flos) together with the calyxes (primrose flowers — Primulae flos cum calyce) are used medicinally.
The European Medicines Agency's HMPC covers primula root preparations obtained by drying and comminuting the underground parts, or by extracting compounds using solvents such as ethanol or methanol to form liquid extracts; the solvent is then fully or partially evaporated to obtain dry or soft extracts. Medicines containing these preparations are usually available as herbal tea to be drunk and in liquid or solid forms to be taken by mouth.
Recognized forms include cut and dried primula flowers for infusions, primula flower tincture, primula root preparations, and primula leaf juice. Primula flowers are usually used in combination with other herbal substances; the primula content in herbal teas varies from 10% to 30%, while in liquid preparations it is about 1%.
2. Traditional and Historical Use
2.1 European Folk and Herbal Medicine
Primula veris is an important medicinal plant with documented use for the treatment of gout, headache, and migraine reaching back to the Middle Ages. Used against palsy in medieval times, cowslip has had a long history based largely on its anti-inflammatory, pain-killing, and fever-reducing effects.
Early herbalists referred to it as Herba paralysis, utilizing it for conditions involving tremors, spasms, and "palsy." Hildegard of Bingen, the famed 12th-century mystic and healer, recommended primrose to dispel melancholy and lift the spirits of those suffering from deep sadness.
In medieval times, primula was used to treat conditions involving spasms, cramps, paralysis, and rheumatic pain. In 1653, the English herbalist Nicholas Culpeper recommended it for treating spasms, cramps, paralysis, and rheumatic pain, also calling it "as fine a salve to heal wound[s] as any I know." He prescribed the flowers for "all infirmities of the head," and the leaves as a beauty treatment. The flowers were made into a wine taken as a sedative and nervine.
In traditional Spanish cooking, cowslip leaves were used as a salad green. Its flowers were also used in England to flavour wine and vinegars. Traditionally, cowslip leaves and flowers were used for skin problems. It was also a remedy for depression and has sedative properties. Historically, it was recommended for people suffering from paralysis.
2.2 Use in Northern and Central Europe
Primula veris infusion, decoction, and tincture are used traditionally as antitussives, mucolytics, and secretolytics. In Denmark, the distilled water obtained from flowers and the infusion of fresh or dry plants were used against headache, epileptic seizures, and insomnia.
The underground organs of P. veris and P. elatior were introduced into European phytotherapy after World War I as a substitute for Senegae radix. Since those days, the herbal substance and several preparations have been in continuous medicinal use, with evidence of at least 30 years of medicinal use, including 15 years within the European Community, verified.
2.3 Culinary and Other Traditional Uses
In ancient times, primula flowers and leaves were also eaten raw or cooked, as the plant is an abundant source of microelements and vitamins. Historically, primula flowers were used to flavor and color wines and cordials, and were part of various folk remedies across Europe.
3. Phytochemistry: Key Constituents and Active Compounds
3.1 Triterpene Saponins
The dried roots contain significant amounts of triterpene saponins, such as primula acid I/II; in the flower, these constituents are located in the sepals, while the dominating constituents of the petals are flavonoids. Cowslip is known for its species-specific saponins; so far, primula acids (primulasaponin) I and II, priverosaponin B, priverosaponin B-22-acetate, and primacrosaponin have been isolated from P. veris.
Various phenolic compounds (flavones, acetophenones, phenolic glycosides, and bisbibenzyls) and saponins closely related to primulasaponin I are present in the roots of Primula veris of Bulgarian origin, among them three triterpene saponins found to be new, previously undescribed compounds.
3.2 Phenolic Glycosides
The roots of Primula veris contain several glycosides of 5-methoxysalicylic methyl ester, such as primeverin and primulaverin. In the crude dried root, their phenolic aglycones are responsible for the typical odour reminiscent of methyl salicylate or anethole.
Primula species produce various polyphenolic compounds including flavonoids as mono-, di-, and tri-glycosides; phenolic acids; and phenolic glycosides (primulaverin and primeverin), as well as epicuticular flavonoids accumulated on the external surface of the plant and mainly aglycones substituted with hydroxy, methoxy, methylenedioxy, and acetyl groups. These compounds exhibit anti-asthmatic, anti-inflammatory, antiviral, antioxidant, and antigenotoxic activities.
3.3 Flavonoids
The flowers were found to contain mainly flavonoids — isorhamnetin, quercetin, and kaempferol triglycosides — with varied population contents, generally higher in northwestern population samples with a colder and more humid climate, all in line with the European Medicines Agency's (EMA) reports.
Previous studies reported the petal pigment kaempferol-3-gentiotrioside from P. veris and 39 further Primula species. Furthermore, the leaf pigment quercetin-3-O-rutinoside was also found in P. veris. Additional flavonoids include apigenin, isorhamnetin (as isorhamnetin-3-O-glucoside and isorhamnetin-3-O-rutinoside), luteolin, and kaempferol in various glycosidic forms.
3.4 Other Constituents
Other identified constituents include volatile oils (in traces), tannins, silicic acid, salicylic acid derivatives, vitamin C, and minerals. Volemitol and heptitol are important components present in all plant parts of Primula species, with the highest concentration found in leaves. Primula species also contain large quantities of tannins, terpenes, alkaloids, and phenolic compounds.
4. Mechanisms of Action
4.1 Expectorant and Secretolytic Action
Triterpenoid saponins — such as primulic acids I/II and priverosaponin B — are considered the main bioactive molecules responsible for the expectorant mechanism of action, which has not yet been fully explained. The proposed mechanism involves irritation of the gastric mucosa and mucous membranes in the throat and respiratory tract, followed by an increase in bronchial secretion as well as a decrease in the viscosity of sputum due to the surface-tension-lowering action of the saponins.
After oral administration, saponins irritate the stomach mucous membrane and trigger a reflex response with enhancement of respiratory secretion through an afferent stimulus. These processes result in an increased intracellular cAMP level, which subsequently elevates surfactant production, leading to decreased mucus viscosity and secretion in alveolar type II cells — which may explain the secretolytic and bronchospasmolytic effect of these saponins.
An undefined mixture of saponins from primula root, at a concentration of 1:10,000, increased the ciliary activity of throat epithelium of curarised frog; this effect was explained by a reduced mucus surface tension.
In general, saponins are poorly absorbed by the body. Glycosidic bonds are usually easily cleaved by enzymes of the gastrointestinal tract, and the amount of absorption depends on the galenic form of the preparation.
4.2 Anti-inflammatory Mechanisms
A Primulae flos dry extract (PFE) was tested in vitro for inhibition of prostaglandin biosynthesis by cyclooxygenases (COX-1 and COX-2) and for inhibition of leukotriene biosynthesis in human polymorphonuclear leukocytes; the T-cell mediated release of the pro-inflammatory cytokines IFN-γ and GM-CSF from human peripheral blood mononuclear cells was also studied after incubation with PFE.
Reduced secretion of certain mucins (mainly MUC5AC, MUC2, MUC19) was demonstrated for the fixed combination of Thymi herba and Primulae radix extracts in various cell cultures.
4.3 Antimicrobial and Antibiofilm Activity
In vitro antimicrobial activity of a Primulae flos dry extract was studied in virus plaque-reduction assays targeting human rhinovirus (HRV) and respiratory syncytial virus (RSV), and in microdilution assays for minimum bactericidal concentration (MBC) against Staphylococcus aureus, Staphylococcus epidermidis, and Streptococcus pneumoniae.
The antibiofilm properties of the chloroform and methanol extracts and the saponin-enriched fraction obtained from the roots of P. veris were studied; the results revealed better biofilm inhibition of tested samples against Gram-negative bacterial strains (P. aeruginosa and E. coli) than Gram-positive ones (S. aureus and S. mutans). Minimum inhibitory and minimum bactericidal concentrations of the chloroform and methanol extracts and the saponin-enriched fraction of P. veris roots were determined, with MIC values ranging between 0.5 and 1 mg/mL.
5. Scientific Evidence by Area of Use
5.1 Respiratory Conditions: Cough and Bronchitis
EMA Regulatory Status: The HMPC concluded that, on the basis of its long-standing use, primula flower preparations can be used as an expectorant (a medicine that helps bring up phlegm) for coughs associated with colds. The quality of primrose root (Primulae radix) is specified in the European Pharmacopoeia, and the quality of primrose root tincture is specified in the German Drug Codex.
Animal/Preclinical Evidence: The expectorant assay was performed with phenol red secretion in the mouse trachea. After gastric administration of test extracts, the results showed that a thick extract of primrose rhizomes with roots has a high ability to secrete sputum, comparable to 126.6% of the Hedelix drops (ivy extract) comparator, rated at 146.4%. Extract from the leaves of P. veris showed less pronounced activity, reaching 74.5% at a dose of 200 mg/kg. The study concluded that triterpene saponins may be the main active ingredients of Primula veris responsible for its expectorant bioactivity.
Clinical Evidence — Cowslip Root with Thyme (Bronchipret): Developing research suggests that taking cowslip root in combination with thyme (Bronchipret) by mouth relieves symptoms of bronchitis, such as coughing, fever, and increased production of mucus. More evidence is needed to rate cowslip for this use independently.
Evidence Strength: Clinical studies with preparations containing solely primula flowers do not exist. The data generated in clinical trials with the special preparation "Sinupret" cannot be included in the assessment of primula flower alone, because the contribution of the primula flower extract to the overall activity cannot be separated. The EMA classification of primula root and flower as traditional herbal medicinal products reflects this limitation: efficacy is recognized based on long-standing use, not on independent, placebo-controlled trials of the single herb.
5.2 Sinusitis (Rhinosinusitis)
Sinupret contains extracts of five traditional European herbs: elder (Sambucus nigra) flowers, primrose (Primula veris) flowers with calyx, common sorrel (Rumex acetosa) herb, European vervain (Verbena officinalis) herb, and gentian (Gentiana lutea) root. Sinupret was approved by the German Commission E in 1994 for the treatment of acute and chronic inflammation of the paranasal sinuses; it is used as a mucolytic with antiviral and anti-inflammatory properties.
Studies of Sinupret reviewed in an American Botanical Council monograph include four clinical trials regarding acute sinusitis, two clinical trials regarding chronic sinusitis, one meta-analysis of clinical trials evaluating treatment of sinusitis, two clinical trials regarding bronchitis, and a post-marketing surveillance study of patients with bronchitis.
Primrose flower is a key active ingredient in one of the most widely researched standardized herbal medicines in Europe (studied under the clinical name BNO 1016 or Sinupret). In multiple randomized, double-blind, placebo-controlled, multicenter clinical trials, this primrose-based formulation demonstrated significant efficacy over placebo in treating acute viral rhinosinusitis.
A placebo-controlled, randomized, double-blind clinical trial with Sinupret sugar-coated tablets on the basis of a therapy with antibiotics and decongestant nasal drops in acute sinusitis was published in Phytomedicine, 1994;1:177–81.
One study of 64 children evaluated 32 using amoxicillin alone and 32 using amoxicillin plus Sinupret; the Sinupret group seemed to show more effective properties and reduced the frequency of complications. A second integrative study of 40 children with a mean age of 4.5 years found similar results, suggesting this herbal combination may be a reasonable choice for children already started on antibiotic medication.
Evidence Strength: The clinical evidence for sinusitis relates specifically to the multi-herb combination product Sinupret, not to cowslip as a monotherapy. The contribution of the cowslip fraction within the combination cannot be separately established from these trials, as noted by the EMA's HMPC assessment. Its efficacy has been tested in three large studies showing positive efficacy.
5.3 Nervous System and Sedative Use
Cowslip flower is used traditionally for insomnia, nervous excitability, headache, hysteria, neuralgia, and tremors. For Primula veris specifically, no sedative effects were observed in studies, and no alteration of stress responses could be detected. This indicates that the traditional sedative reputation lacks formal scientific validation in available controlled studies.
5.4 Antioxidant and Anti-inflammatory Properties (In Vitro)
Saponins are responsible for secretolytic and expectorant activity; phenolic compounds in primula flowers are responsible for antioxidant, antimicrobial, and cytostatic properties. In studies of the fresh above-ground sections of Primula veris, the total ascorbic acid content was determined as 118 mg/100 g, and the FRAP value was determined at 757 µmol Fe II/g. These findings are from in vitro and analytical studies; no clinical evidence of antioxidant efficacy in humans has been established.
5.5 Cytotoxic Activity (In Vitro Only)
Researchers showed that the isorhamnetin aglycone present in the plant shows cytotoxic activity toward human hepatocellular carcinoma cells. This finding is preliminary, limited to in vitro investigation only, and carries no established clinical relevance for human oncology use.
5.6 Skin and Wound Healing
In folk medicine, Primula vulgaris leaves and root extract are used to treat skin problems, ulcers, and in wound healing. These claims derive from folk use only, with no controlled human clinical evidence currently available in the published literature reviewed.
6. Body Systems Associated with Cowslip
- Respiratory system: Infusions and decoctions have been traditionally used as expectorants in cases of cough, asthma, bronchitis, and catarrh.
- Nervous system: Cowslip flower is used orally for insomnia, nervous excitability, headache, hysteria, neuralgia, and tremors, though scientific support for these uses is absent.
- Immune and sinus system: In combination with gentian root, European elder flower, verbena, and sorrel, cowslip is used orally for maintaining healthy sinuses and treating sinusitis.
- Integumentary (skin) system: Traditionally, cowslip leaves and flowers were used for skin problems.
- Musculoskeletal system: Cowslip has had a long history based largely on its anti-inflammatory, pain-killing, and fever-reducing effects.
- Urinary system: Herre (1937) published some data in rats concerning diuretic properties of Primula officinalis (= Primula veris), but there are no more recent investigations which endorse these findings.
7. Dosage Forms and Reported Dosages
German Commission E (dried herb): The German Commission E recommends one to two teaspoons of dried primrose flowers, or one teaspoon of the plant's dried root, as a respiratory remedy for laryngitis, bronchitis, colds, and coughs.
Root tincture: According to the German Commission E, primrose root tincture is recommended at a daily dosage of 1.5 to 3 grams.
Sinusitis combination product (Sinupret): Specific combination products (SinuComp, Sinupret, Sinupret+) have been used at doses providing 36 mg of cowslip flower, 12 mg of gentian root, and 36 mg each of European elder flower, verbena, and sorrel, taken three times daily for 7 days.
Children's dosage (root tincture, as reported in EMA assessment): In clinical study data supporting the EMA monograph on primula root, all children received 150 drops per day, corresponding to approximately 0.2 g primula root. Depending on drop size, the single dose corresponded to 0.3–0.5 mL tincture, and the daily dose to 0.9–1.5 mL tincture.
Pediatric age restriction (flower preparation): No data for a posology in children from clinical trials are available for primula flower preparations; therefore, primula flower should not be used in children up to 12 years of age. Since data available for primula root suggest use for children from 1 year of age, use of primula flower from 12 years could be justified.
Pharmacopeial quality: The quality of primrose root (Primulae radix) is specified in the European Pharmacopoeia, and primrose root tincture (Primulae radicis tinctura) is specified in the German Drug Codex (DAC).
8. Safety Considerations and Interactions
8.1 General Safety Profile
Cowslip is possibly safe for most people when taken by mouth in small amounts as part of a combination product containing gentian root, European elder flower, verbena, and sorrel (SinuComp, Sinupret). There is insufficient information to determine whether cowslip is safe when used in medicinal amounts other than as part of this combination product.
No serious events or deaths are reported in the EMA assessment of primula root.
8.2 Gastrointestinal Effects
Rare side effects of the saponins can include nausea or diarrhoea. The EMA monograph for primula root specifies: "Caution is recommended in patients with gastritis or gastric ulcer."
8.3 Allergic and Contact Reactions
Contact allergic properties have been described for primin and other quinoid compounds, which may be present in the aerial parts of Primula elatior and Primula veris. Both species have primin-free as well as primin-containing individuals. Hypersensitivity against primin could be of clinical relevance.
Contact allergic properties have been described for primin and other quinoid compounds obtained from Primula elatior and Primula veris; however, primin and other quinoid compounds occur in the aerial parts only. The clinical relevance of these contact allergic properties is therefore unlikely for the oral administration of primula root preparations.
The medically used primula species contain almost no primin. The main primin allergy concern in dermatology literature is associated with Primula obconica, the ornamental species, rather than P. veris. Primin (2-methoxy-6-pentyl-1,4-benzoquinone) is the main sensitizer in the Primula genus, although other allergens have been postulated.
A database search of the Austrian medicines and medical devices agency had only 3 reports of adverse effects referring to preparations containing primula, all concerning a combination product containing Primulae flos, gentian, sorrel, elder, and verbena. The adverse effects cannot be exclusively assigned to primula flower, as the contribution of the combination partners is not known.
8.4 Pregnancy and Lactation
There is insufficient reliable information available regarding the safety of cowslip in pregnancy and lactation; use during these periods should be avoided.
8.5 Drug Interactions
No drug interactions with primula root have been reported in the EMA assessment. Side effects associated with the Sinupret combination product have included kidney stones, allergic reactions, gastrointestinal symptoms, numbness, and mild dermatitis; interactions have been noted with therapeutic monoclonal antibodies, hypertensive medications, and immunosuppressants — though these pertain to the combination product and cannot be attributed exclusively to cowslip. The roots are noted not to be taken with aspirin, as they are high in salicylates.
8.6 Pharmacokinetics
In general, saponins are poorly absorbed by the body. Glycosidic bonds are usually easily cleaved by enzymes of the gastrointestinal tract, and the amount of absorption depends on the galenic form of the preparation. No specific data are available on the pharmacokinetics of primula flower saponins in humans, according to the EMA draft assessment report.
References
Go back